Digital health news, funding roundup in the prior week; December 06, 2021
Harrison.ai raised $92.3 million USD, Droplette secured $15.4M,
Read more...If you are interested in being included in our funding roundup, submit your press release or blog post about your financing round to mitos@vator.tv.
Image source: www.digital.je
I produce Vator Events and enjoy the challenge. I am learning and growing a lot, being involved with Vator and loving every moment of it!
All author postsHarrison.ai raised $92.3 million USD, Droplette secured $15.4M,
Read more...Amazon Health sells healthcare services to Hilton; Athenahealth acquired for $17 Billion
Read more...How Microsoft can transform healthcare delivery; Trusted has raised $94M; Aptihealth landed $50
Read more...Angel group/VC
Joined Vator on
There’s a simple premise behind the founding of General Catalyst (GC) in 2000: entrepreneurs are best served by those who've been in their shoes. In fact, all of GC’s managing directors are accomplished entrepreneurs in their own right. We’re familiar with the challenges you face. And we thrive on our ability to use our entrepreneurial experience to assist, guide, and nurture entrepreneurs on their journey.
As a venture capital firm focusing on Early Stage and XIR/Growth investments, we're thrilled to encounter and delight in helping exceptional entrepreneurs and innovative companies bring a new product to market or transform an industry. But it’s more than just writing a big check. We're tireless in our business-building and partnership development assistance.
Angel group/VC
Joined Vator on
Sequoia Capital is a venture capital firm founded by Don Valentine in 1972. The Wall Street Journal has called Sequoia Capital “one of the highest-caliber venture firms” and noted that it is “one of Silicon Valley’s most influential venture-capital firms”. It invests between $100,000 and $1 million in seed stage, between $1 million and $10 million in early stage, and between $10 million and $100 million in growth stage.
Angel group/VC
Joined Vator on
NEA is the entrepreneur’s venture capital firm.
When it is time to take a promising business or business idea to the next level, entrepreneurs want a venture partner who understands and believes in the power of big dreams, bold visions and fresh ideas that have the power to change an industry, a sector, the world.
Moreover, entrepreneurs want a venture partner who knows what it takes—through first-hand experience and carefully nurtured relationships—to make a company succeed, to turn an idea into an action, and to make a plan a reality.
For more than 30 years, NEA has been helping to build great companies. Our committed capital has grown to $13 billion, including a $2.6 billion fourteenth fund closed in 2012. We invest across stage and geography in technology, healthcare and energy.
Remaining nimble as we’ve grown—with more than 65 investment professionals working out of our offices in the US, India, and China and investing across the globe—NEA is the entrepreneur's venture capital firm, consistently ranking among the top firms in portfolio IPOs each year. Since its founding, the firm has backed more than 175 companies that have gone public and invested in more than 290 companies that have been successfully merged or acquired—more liquidity events than any other venture capital firm.
Whether you are seeking investment to get your idea off the ground or looking to propel a proven idea toward greatness, NEA is the venture partner who will be there—because we’ve been there—every step of the way.
Angel group/VC
Joined Vator on
Scale Venture Partners chooses markets for investment based on our insights into trends drawn from primary research with incumbents, customers, competitors and our network of experts. We select companies we think are going after something great. Our investment strategy makes "scale" relevant to you for two reasons. We operate in markets where you can create large scale success. We work side by side with you to help scale your business to reach its market potential. |
Most of our investments are mid to late stage, when the software is being used, the chip is in the fab, and the therapy is being tested on humans. It may still feel early to you. You may be just starting to build out your go-to-market team. It's at this stage that our own practical operating experience drives the best rewards. |